NewsCura

Ginebra San Miguel, Inc.

Disclaimer: The research and recommendation below were generated by Claude Fable. Please treat this as one input for your own research — not as the sole basis for any decision to buy or sell a stock.

Last checked
Price
260.4000
Trading status
Normal
Recommendation
Buy (12-year compounder at ~8x; thin float, enter patiently)Buy
Committee call
Buy
Indices
MidCap

Analysis

GSMI - Ginebra San Miguel, Inc.

One-line summary: The world's largest gin producer by volume keeps compounding (12 straight years of volume growth, 20% net income growth in 2025, a debt-free balance sheet) yet trades at roughly 8 times trailing earnings, because a controlling parent and a public float below 25% keep the stock quiet and thinly traded.

Snapshot
Reviewed July 19, 2026
Index membership PSE MidCap
Price at review P260.40 (July 17, 2026 close, last trading session before this review; up from P253.00 on July 10; 52-week range P252.20-P305.00)
Recommendation Buy (quality compounder at a single-digit multiple; enter patiently given thin trading)
Market cap ~P74.6B (286.33M shares)
Trailing P/E ~8.4x
Estimated forward P/E (2026) Not published (thin analyst coverage); if net income keeps growing at the Q1 pace (+9%), the multiple would compress further from an already-low base
Dividend (trailing) P16.50/share (four quarterly payments, most recently raised to P4.50, paid June 5, 2026), ~6.3% yield
P/B ~2.75x
Debt Essentially none (D/E ~0.00-0.06; ~P17.85B cash against ~P39.6M debt)

Core business: the world's biggest gin maker, still growing volume every year

Ginebra San Miguel is the flagship spirits unit of San Miguel Food and Beverage (itself under San Miguel Corporation, ultimate parent Top Frontier Investment Holdings). Its portfolio spans Ginebra San Miguel gin, the world's largest-selling gin by volume, GSM Blue (a lighter, younger-skewing gin that Drinks International has ranked the world's fastest-growing gin brand), Primera Light Brandy, and Vino Kulafu. The company sold a record 51 million cases in 2025, its 12th consecutive year of volume growth, and dominates the domestic hard-liquor market, historically strongest in Luzon and expanding into the Visayas and Mindanao through campaigns like "Kabayani Kita sa One Ginebra Nation."

Revenue and earnings: pricing power on top of volume growth

Revenue: P42.5B (2021), P47.3B (2022), P53.6B (2023), P62.5B (2024), P67.4B (2025), TTM P67.8B. Net income: P4.2B (2021), P4.5B (2022), P7.0B (2023), P7.3B (2024), P8.7B (2025), TTM P8.9B, a roughly doubling of profit over five years with net margin expanding from 9.8% to 12.9%. Q1 2026 kept the streak going: net income up 9% to P2.29B on revenue up 3% to P16.7B, with gross profit up 11% as management pointed to better selling prices, lower molasses costs, and improved distillery efficiencies. Full-year 2025 operating income rose 21% and Q1 2026 operating margin expanded to roughly 17% from 15% a year earlier. This is not a one-off: pricing discipline plus steady volume has driven growth every year since at least 2021, through PH consumer softness that has hurt names like Emperador and Universal Robina.

Dividend sustainability: raised, and comfortably covered

Quarterly dividends: P4.00/share through most of 2025 (ex-dates in February, May, August, and November 2025) and into Q1 2026 (ex March 19, 2026), then raised to P4.50/share for the dividend paid June 5, 2026 (ex May 18, 2026), a 10% step up. On a trailing four-quarter basis that is P16.50/share, a ~6.3% yield at the current price. No new dividend has been declared since; the next declaration is not expected until roughly August, alongside Q2 2026 results. Payout ratio, measured against cash dividends actually paid in the fiscal year, has run 24-39% since 2022 (31.94% in 2025), and free cash flow covered the FY2025 dividend by nearly 2.7 times (P7.49B FCF vs P2.77B paid). Cash dividends paid have grown from P278M (2021) to P2.77B (2025), a tenfold increase that tracks the earnings growth rather than outrunning it. This is a dividend with room to keep growing, not one propped up by leverage.

ROE: consistently high, not flattered by debt

ROE: 39.85% (2021), 35.03% (2022), 42.91% (2023), 35.98% (2024), 36.19% (2025). ROA has stayed in the 17-20% range across the same period. Debt/equity has hovered near zero the entire five years (0.00-0.06), so this is a genuinely high-return business, not a leveraged one. A distiller compounding above 35% ROE on an unlevered balance sheet is a rare combination on the PSE.

Free cash flow: low capital intensity, high conversion

Operating cash flow: P2.5B (2021), P7.3B (2022), P6.8B (2023), P7.1B (2024), P8.6B (2025). Capex has stayed modest throughout: P0.6B (2021), P1.0B (2022), P1.0B (2023), P2.0B (2024), P1.2B (2025), reflecting bottling and distillery efficiency investments rather than heavy new capacity. Free cash flow: P1.9B (2021), P6.3B (2022), P5.9B (2023), P5.2B (2024), P7.5B (2025), an 87% conversion rate from operating cash flow in the latest year. This is a business that throws off cash well in excess of what it needs to reinvest.

Capital allocation and ownership: controlled, debt-free, thin float

San Miguel Food and Beverage runs Ginebra San Miguel as one of its three main divisions (alongside San Miguel Foods and San Miguel Brewery), under the ultimate control of San Miguel Corporation and Top Frontier Investment Holdings. The balance sheet is essentially debt-free (P17.85B cash against P39.6M debt), and capital return has scaled with earnings (dividends paid up roughly tenfold since 2021) rather than through buybacks, which have not been a feature here.

The catch is liquidity. Public float is confirmed at 24.09% (PSE Edge, July 17, 2026), just above the PSE's 20% minimum for continued index eligibility. Twenty-day average volume is only about 62,000 shares a day, on the order of P15-16M in traded value daily against a P74.6B market cap, thin even by PH mid-cap standards. That thinness likely explains why a company posting record profit and a 12-year volume growth streak still trades well off its 52-week high of P305.00 (currently about 14.6% below it, having ticked up from P253.00 to P260.40 over the past week on no identifiable news): there simply aren't enough shares changing hands for the market to re-rate the stock quickly, and thin analyst coverage means no published forward P/E consensus. Wider bid-ask spreads and a real risk that a position takes a while to build or exit at size are the price of admission.

Comparison with EMI: same PH-spirits box, opposite fundamentals

EMI (Emperador, reviewed today at P15.52, Sell) and GSMI are both controlled spirits makers with thin public floats, but the resemblance stops there. EMI trades at roughly 62x trailing earnings on a business whose net income has fallen about 61% since 2022, with a dividend cut three years running and free cash flow that hasn't covered the dividend for two straight years. GSMI trades at roughly 8x trailing earnings on a business that grew net income 20% in 2025, kept extending a 12-year volume growth streak, just raised its dividend, and sits on a debt-free balance sheet. Where EMI's illiquidity compounds an already weak fundamental case, GSMI's illiquidity is the main blemish on an otherwise clean one, and it is the reason the multiple stays this cheap.

Verdict at P260.40 (July 19, 2026)

Buy, unchanged. The stock drifted up from P253.00 to P260.40 over the week since the July 12 review, but nothing fundamental moved: no new disclosures, no dividend declaration since the P4.50 paid June 5, 2026, and no Q2 2026 results yet (both are expected around August). Neither buy trigger nor sell trigger below has fired: the volume growth streak, ROE, and dividend are all intact, and public float is confirmed at 24.09%, comfortably above the PSE's 20% minimum. A gin monopoly-adjacent business growing volume every year since at least 2014, earning 35%+ ROE on an unlevered balance sheet, converting cash at a high rate, and raising its dividend, trading at roughly 8.4x trailing earnings and under 3x book, is statistically cheap by almost any measure. The reason it stays cheap is liquidity, not fundamentals: a ~24% public float and ~62,000 shares of daily volume mean the market is not pricing this stock efficiently, and there is no guarantee that changes soon. Buy for the compounding and the covered, growing dividend, not for a near-term re-rating. Size positions with the thin float in mind, expect wide spreads, and be patient about both entry and exit.

What would change the call:

  • Buy trigger: further weakness toward the P230-240 area (deeper discount to an already-cheap multiple) with the volume growth streak and margins still intact; or a stock split or float-widening move that improves liquidity without hurting fundamentals.
  • Sell trigger: the volume growth streak breaks (a year of falling case volumes), ROE falls under 25%, the dividend is cut, or the public float drifts toward or below the PSE's 20% minimum, raising index-exclusion risk.

Analysis, not financial advice.

Committee review (July 19, 2026)

Five investor lenses judged this page's facts independently, each reasoning strictly inside its own framework with no cross-talk between them.

Lens Signal Confidence Core argument
Ben Graham Neutral 55 Conservative-financing and earnings-stability tests still pass cleanly (near-zero debt/equity, net income up every year from P4.2B in 2021 to P8.7B in 2025), and the margin-of-safety screen (P/E times P/B under ~22.5) has moved closer to passing as book value grows: 8.4x trailing P/E times a P/B of 2.75x is now about 23.1, near the threshold rather than well past it, but still not a clean pass.
Warren Buffett Bullish 85 35%+ ROE on almost no debt (P17.85B cash vs P39.6M debt) signals a real moat rather than leverage-driven returns, and net income growing from P4.2B to P8.7B (2021-2025) with FCF covering the dividend 2.7x makes an 8.4x trailing multiple look mispriced for a quality compounder, whether the price is P253 or P260.
Michael Burry Bullish 74 The book-value discount has actually widened in the business's favor: P/B has come down to 2.75x (from 3.2-3.6x a week ago) as retained earnings build, while the balance sheet (P17.85B cash vs P39.6M debt) and 36%+ ROE are unchanged; an 8.4x earnings multiple against under 3x book on a cash-rich, debt-free compounder is exactly the disconnect this lens hunts for.
Nassim Taleb Bullish 63 Zero refinancing fragility (P17.85B cash vs P39.6M debt) and controlling-family skin in the game cushion the downside, while 12 years of volume growth and 2.7x dividend coverage at 8.4x earnings offer convex upside if the market ever re-rates it; the one true fragility is the ~24% float sitting barely above the PSE's 20% minimum, a position-level tail risk rather than a business one.
Stanley Druckenmiller Neutral 40 Business quality is real (35%+ ROE, debt-free, 8.4x trailing P/E), but there's still no catalyst: the week's ~2.9% price tick has no identifiable news behind it, no disclosures or dividend declaration have landed since May, and ~62,000 shares/day of volume against a P74.6B cap make cheapness alone insufficient without an event to force capital in.

Conferred call: Buy (3 bullish, 2 neutral, 0 bearish). Unchanged from the July 12 run and still matches the page's Recommendation; the split reflects a real tension in the rulebook (Brain/concepts/stock-trading-strategy-and-rules.md) between "cheap at the lows" being a trap versus a genuine mispricing, a tension this page resolves by requiring a catalyst-agnostic, patience-based entry rather than a near-term re-rating thesis.

Shared flip trigger: every bullish and neutral lens separately flagged the ~24% public float sitting just above the PSE's 20% index-eligibility minimum as the position's central risk; a further drift toward that floor would be the first sign to reassess regardless of lens.

Review history

Date Price Recommendation
July 10, 2026 253.00 Buy (quality compounder at ~8x earnings; thin liquidity, enter patiently)
July 12, 2026 253.00 Buy (unchanged; no material news since July 10, committee reconfirms 3 bullish, 2 neutral)
July 19, 2026 260.40 Buy (unchanged; price drifted up on no news, no new dividend or Q2 results yet, committee reconfirms 3 bullish, 2 neutral)

Sources